COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Treatment on Decision-making in Major Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01916824
Recruitment Status : Completed
First Posted : August 6, 2013
Results First Posted : October 20, 2017
Last Update Posted : November 21, 2017
Information provided by (Responsible Party):
Boadie W. Dunlop, Emory University

Brief Summary:
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their decision-making styles. There will be three visits for depressed patients and two for healthy controls (the first and third visits). The first visit will involve interviews and questionnaires to assess the participant's level of depression, medical history and quality of life. Participants will then complete the decision-making tasks, and will earn between $5-40 based on their choices, in order to make the decisions on the computer tasks financially meaningful. At the completion of this visit, depressed patients will be prescribed an FDA-approved antidepressant, chosen in consultation with the treating psychiatrist. Patients will be responsible for paying for the prescription themselves. After two weeks on the medication, the patient will be seen for a follow-up visit to ensure tolerability of the medicine. After six weeks on the medicine, patients and healthy controls will return to repeat the questionnaires and the computer based decision-making tasks, and will again earn between $5-40 based on their performance.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Healthy Controls Drug: Any FDA Approved Antidepressant Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Effects of Treatment on Decision-making in Major Depression
Study Start Date : August 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Arm Intervention/treatment
Experimental: Participants with Major Depressive Disorder
Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
Drug: Any FDA Approved Antidepressant
Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
Other Names:
  • Sertraline, Zoloft
  • Citalopram, Celexa
  • Escitalopram, Lexapro
  • Paroxetine, Paxil
  • Fluoxetine, Prozac
  • Vilazodone, Viibryd
  • Venlafaxine XR, Effexor XR
  • Desvenlafaxine, Pristiq
  • Duloxetine, Cymbalta
  • Bupropion, Wellbutrin
  • Mirtazapine, Remeron

No Intervention: Healthy Controls
Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness

Primary Outcome Measures :
  1. Money Earned [ Time Frame: Baseline, Week 6 ]

    Change in amount of money earned between baseline and after 6 weeks of antidepressant treatment is determined through a summary score from a variety of decision-making tasks. Participants received between $5 and $40 per visit, depending on the outcomes of the decisions made on the computerized tasks. Variable payment ensured that the decision-making tasks were approached realistically, as opposed to using hypothetical "points" that do not have meaning in the real world. Greater earnings indicate better financial decision-making.

    The specific tasks were:

    1. risk task
    2. balloon analogue risk task
    3. temporal discounting task
    4. ultimatum game
    5. continuous performance task

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria for MDD Subjects:

  1. Male or female, age 18-65
  2. Primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) Diagnosis of Major Depressive Disorder.
  3. Has a 17-item Hamilton depression rating scale (HDRS-17) score >=16.
  4. Ability to visually read and understand English language
  5. Not currently taking an antidepressant.
  6. Women of reproductive potential must be willing to take a medically approved form of birth control throughout the duration of the study.

Inclusion Criteria for Healthy Control Subjects:

  1. Male or female, age 18-65
  2. No current DSM-IV TR diagnosis of a mental illness.
  3. No lifetime history of Major Depressive Disorder or Dysthymia.
  4. Has a 17-item Hamilton depression rating scale (HDRS-17) score ≤7.
  5. Ability to visually read and understand English language
  6. Not currently taking any psychoactive medication

Exclusion Criteria for all subjects:

  1. Has met criteria at any time during their life for bipolar disorder, a primary psychotic disorder (e.g. schizophrenia), or dementia.
  2. Meet criteria for substance abuse or dependence within three months of the screening visit.
  3. Presents with a clinically significant suicide risk, as assessed by a study physician.
  4. Presence of any unstable or central nervous system-related medical illness that would interfere with cognition or participation.
  5. Women who are currently pregnant or lactating, or plan to become pregnant during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01916824

Layout table for location information
United States, Georgia
Emory Mood and Anxiety Disorders Program
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Layout table for investigator information
Principal Investigator: Boadie W Dunlop, MD Emory University
Additional Information:
Layout table for additonal information
Responsible Party: Boadie W. Dunlop, Principal Investigator, Emory University Identifier: NCT01916824    
Other Study ID Numbers: IRB00066705
First Posted: August 6, 2013    Key Record Dates
Results First Posted: October 20, 2017
Last Update Posted: November 21, 2017
Last Verified: October 2017
Keywords provided by Boadie W. Dunlop, Emory University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Duloxetine Hydrochloride
Venlafaxine Hydrochloride
Antidepressive Agents
Desvenlafaxine Succinate
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Psychotropic Drugs
Peripheral Nervous System Agents
Dopamine Uptake Inhibitors
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors